Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”)  is pleased to announce that it presented a joint study result regarding ovarian cancer with Shinichi Tate, Associate Professor at Chiba University Hospital, at “ESMO Congress 2021,” held online in Paris, France from September 16th to September 21st. With the result of this study, Craif will aim to implement an ovarian cancer test using urinary miRNA.

■ Joint Study with Chiba University
Chiba University and Craif are conducting a clinical study to analyze urinary miRNA in ovarian cancer patients using microfluidic nanowire devices since 2019. In this study, the following results were reported: 1) many useful ovarian cancer biomarker candidates were identified by urinary miRNA analysis, 2) through conducting an assessment of urinary miRNA expression by the RT-qPCR method, we successfully detected early stage ovarian cancer with high accuracy (AUC 0.98), 3) this method was found to be effective in detecting stage 1 ovarian cancer with high sensitivity.

■ Outline of “ESMO Congress 2021”
ESMO is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all around the world. In 2020, due to unprecedented environment regarding COVID19, a comprehensive, scientific and educational program was conducted virtually. ESMO aims to deliver new data in oncology to the world in real time, and to promote professional education in oncology.

The ESMO Congress 2021 will showcase the latest advances in cancer treatment and provide an opportunity for delegates from all over the world to exchange ideas and opinions in an interactive environment.

[Dates] September 16th – September 21st, 2021
[Venue] Paris/France (online), Paris Expo Porte des Versailles
[Official Website] https://www.esmo.org/meetings/esmo-congress-2021